Navigation Links
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Date:7/11/2012

TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EDT that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for EYLEA and ARCALYST and for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:Manisha Narasimhan, Ph.D. 

Peter DworkinInvestor RelationsCorporate Communications914-847-512914.847.764Manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces June 2012 Investor Conference Presentations
2. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
3. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
4. China Pharmaceuticals and Healthcare Report Q3 2012
5. Questcor to Report Second Quarter Results on July 24, 2012
6. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
7. India Pharmaceuticals and Healthcare Report Q3 2012
8. Par Pharmaceutical Companies to Report Second Quarter 2012 Results on August 2, 2012
9. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
10. Draeger Welcomes NIOSH Investigation Report
11. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
(Date:7/26/2017)... , July 26, 2017 The Galien ... Prix Galien USA Award Nominees. Counted ... Prix Galien Award recognizes outstanding biomedical and technology product achievement ... To qualify, each candidate must be U.S. Food ... five years and demonstrate tremendous potential to impact human health. ...
Breaking Medicine Technology:
(Date:8/18/2017)... New York (PRWEB) , ... August 18, 2017 ... ... leading manufacturers and marketers of high-quality anti-aging skincare solutions, recently announced ... Serum. These new products are an affordable, yet effective alternative to expensive plastic ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Case ... Veterans Affairs Medical Center. “Case #10-5411 Veterans Administration” is the creation of ... abuse. In June 1990, Carol Mulhem started work at the Coatesville VAMC ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... organizations and considered extremely effective, very effective, or effective by 85% of respondents, ... , NEJM Catalyst Insights Reports are based on surveys of the NEJM Catalyst ...
(Date:8/17/2017)... ... , ... When Amy Cowperthwait left the emergency room after 28 ... dream to make nursing education more relevant and prepare aspiring nurses to address both ... healthcare provider education. , “The human element was missing. Students were learning ...
Breaking Medicine News(10 mins):